SCHEMBL5349249

SCHEMBL5349249

CN(C(=O)Nc1ccc(Cl)c(Cl)c1)c1ccc(Oc2ccnc(-c3nnco3)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 11/20 0.45
APEX1 P27695 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
BRAF P15056 2/20 0.40
KDR P35968 5/20 0.39
PDGFRA P16234 2/20 0.39
MEN1 O00255 1/20 0.39
PLK4 O00444 1/20 0.39
CIT O14578 1/20 0.39
AURKA O14965 1/20 0.39
MUSK O15146 1/20 0.39
EPHB6 O15197 1/20 0.39
MAPK13 O15264 1/20 0.39
MLNR O43193 1/20 0.39
MAP3K7 O43318 1/20 0.39
RIPK2 O43353 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437656 0.90 RAF1 (0.58) RAF1BRAFKDRPDGFRAMEN1
SCHEMBL5446241 0.87 RAF1 (0.54) RAF1BRAFKDRPDGFRAMEN1
SCHEMBL14447685 0.83 RAF1 (0.50) RAF1BRAFKDRPDGFRAMEN1
SCHEMBL5447334 0.83 RET (0.49) RAF1BRAFKDRPDGFRAMEN1
SCHEMBL5452692 0.79 KDR (0.49) KDRFLT1
SCHEMBL3406605 0.77 RAF1 (0.65) RAF1BRAFKDRPDGFRAMEN1
SCHEMBL5340668 0.75 TLR8 (0.43) RAF1KDM4EALDH1A1HPGDKDR
SCHEMBL6384852 0.73 RAF1 (0.47) RAF1BRAFKDRPDGFRAMEN1
SCHEMBL5443759 0.73 CDK8 (0.43) RAF1ALDH1A1GLAKDRMEN1
SCHEMBL5337325 0.72 RET (0.63) RAF1BRAFKDRPDGFRAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 RAF1 3/4885APEX1 3876/4885KDM4E 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.